Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 3/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.71 |
| ▸ | TOP1 | P11387 | 3/20 | 0.45 |
| ▸ | PIM1 | P11309 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.39 |
| ▸ | FLT4 | P35916 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | RARB | P10826 | 1/20 | 0.39 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2921601 | 0.93 | CYP2C9 (0.62) | CYP2C9CYP3A4TOP1PIM1ALDH1A1 | |
| SCHEMBL2923696 | 0.93 | CYP3A4 (0.62) | CYP2C9CYP3A4TOP1PIM1ALDH1A1 | |
| SCHEMBL2917096 | 0.91 | CYP2C9 (0.60) | CYP2C9CYP3A4TOP1PIM1ALDH1A1 | |
| SCHEMBL7006625 | 0.90 | CYP2C9 (0.63) | CYP2C9CYP3A4TOP1PIM1ALDH1A1 | |
| SCHEMBL4747757 | 0.89 | CYP2C9 (0.69) | CYP2C9CYP3A4TOP1PIM1ALDH1A1 | |
| SCHEMBL2920517 | 0.89 | CYP2C9 (0.63) | CYP2C9CYP3A4TOP1PIM1ALDH1A1 | |
| SCHEMBL2922188 | 0.87 | CYP2C9 (0.60) | CYP2C9CYP3A4TOP1PIM1ALDH1A1 | |
| SCHEMBL14421859 | 0.87 | CYP2C9 (0.66) | CYP2C9CYP3A4TOP1PIM1ALDH1A1 | |
| SCHEMBL7007305 | 0.87 | CYP2C9 (0.66) | CYP2C9CYP3A4TOP1PIM1ALDH1A1 | |
| SCHEMBL7858316 | 0.86 | CYP3A4 (0.55) | CYP2C9CYP3A4TOP1PIM1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1861401-B1 | 7-AMINO ALKYLIDENYL-HETEROCYCLIC QUINOLONES AND NAPHTHYRIDONES | JANSSEN PHARMACEUTICA NV (BE) | 2015-11-18 | — | — | EP | disclosed |
| CN-101622240-B | Fused Substituted Aminopyrrolidine Derivatives | DAIICHI SANKYO CO LTD | 2014-07-23 | — | — | CN | disclosed |
| US-20140142096-A1 | Fused Substituted Aminopyrrolidine Derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-05-22 | — | — | US | disclosed |
| US-8618094-B2 | Fused substituted aminopyrrolidine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-12-31 | — | — | US | disclosed |
| EP-2097400-B1 | FUSED SUBSTITUTED AMINOPYRROLIDINE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2013-07-03 | — | — | EP | disclosed |
| US-20130029977-A9 | Fused substituted aminopyrrolidine derivative | DAIICHI SANKYO COMPANY, LIMITED | 2013-01-31 | — | — | US | disclosed |
| EP-2540715-A1 | Fused substituted aminopyrrolidine derivative | Daiichi Sankyo Company, Limited (JP) | 2013-01-02 | — | — | EP | disclosed |
| US-20120108582-A1 | Fused substituted aminopyrrolidine derivative | DAIICHI SANKYO COMPANY, LIMITED | 2012-05-03 | — | — | US | disclosed |
| US-7902227-B2 | C-7 isoxazolinyl quinolone / naphthyridine derivatives useful as antibacterial agents | JANSSEN PHARMACEUTICA NV. (BE) | 2011-03-08 | — | — | US | disclosed |
| US-7902227-B2 | C-7 isoxazolinyl quinolone / naphthyridine derivatives useful as antibacterial agents | JANSSEN PHARMACEUTICA NV. (BE) | 2011-03-08 | — | — | US | disclosed |
| EP-0992501-B1 | Pyridonecarboxylic acid derivatives as antibacterial agents | WAKUNAGA PHARMA CO LTD (JP) | 2002-08-28 | — | — | EP | disclosed |
| EP-0911327-B1 | NOVEL PYRIDONECARBOXYLIC ACID DERIVATIVES OR THEIR SALTS AND ANTIBACTERIAL AGENT COMPRISING THE SAME AS THE ACTIVE INGREDIENT | WAKUNAGA PHARMA CO LTD (JP) | 2001-12-05 | — | — | EP | disclosed |
| US-6156903-A | Pyridonecarboxylic acid derivatives or their salts, and antibacterial agents containing the same as their effective components | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 2000-12-05 | — | — | US | disclosed |
| US-6136823-A | BACTERICIDES OR VIRICIDES | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 2000-10-24 | — | — | US | disclosed |
| US-6133284-A | EXCELLENT BACTERICIDAL PROPERTIES AND ORAL ABSORPTION; INFECTIONS FROM GRAMNEGATIVE AND -POSITIVE BACTERIA; INTESTINAL ABSORPTION, METABOLIC STABILITY; SIDE EFFECT REDUCTION; NONPHOTOTOXICITY AND NONCYTOTOXICITY | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 2000-10-17 | — | — | US | disclosed |
| EP-0992501-A2 | Pyridonecarboxylic acid derivatives as antibacterial agents | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 2000-04-12 | — | — | EP | disclosed |
| US-5998436-A | Pyridonecarboxylic acid derivatives or their salts and antibacterial agent comprising the same as the active ingredient | WAKUNAGA PHARMACEUTICALS CO., LTD. (JP) | 1999-12-07 | — | — | US | disclosed |
| EP-0952151-A2 | Intermediates for use in preparing novel pyridonecarboxylic acid derivatives or their salts | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 1999-10-27 | — | — | EP | disclosed |
| EP-0945435-A1 | NOVEL PYRIDONECARBOXYLIC ACID DERIVATIVES OR SALTS THEREOF AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 1999-09-29 | — | — | EP | disclosed |
| EP-0911327-A1 | NOVEL PYRIDONECARBOXYLIC ACID DERIVATIVES OR THEIR SALTS AND ANTIBACTERIAL AGENT COMPRISING THE SAME AS THE ACTIVE INGREDIENT | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 1999-04-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108582-A1 | Fused substituted aminopyrrolidine derivative | NQO2, QDPR, IL4I1 | CYP2C9 428/4885CYP3A4 153/4885TOP1 49/4885 |
| US-20140142096-A1 | Fused Substituted Aminopyrrolidine Derivative | NQO2, QDPR, IL4I1 | CYP2C9 428/4885CYP3A4 153/4885TOP1 49/4885 |
| US-20130029977-A9 | Fused substituted aminopyrrolidine derivative | NQO2, QDPR, IL4I1 | CYP2C9 428/4885CYP3A4 153/4885TOP1 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.